QUALIblood

🚀 QUALIblood at ESG 2025 in Riga – Join the Conversation! 🚀 We’re excited to announce that QUALIblood will be attending the ESG 2025 congress! Jonathan Douxfils, Laure Morimont, Marie Didembourg, and Nathalie Donis will be there to share our latest research and engage in meaningful discussions on women's health, contraception, and thrombosis risk assessment. 📢 Our Presentations 📍 Wednesday, March 19 | 18:30 - 20:00 | Poster Session 🤰🏻 Marie Didembourg (P86) – Evaluation of neutralizing antibody titers against SARS-CoV-2 JN.1 Omicron subvariant during pregnancy - A case series study 📍 Saturday, March 22 | 11:45 - 14:00 | Contraception 🩸 Laure Morimont – The nAPCsr, the biomarker for CHC-associated thrombotic risk evaluation 💊 Jonathan Douxfils – Lower reporting of venous thromboembolic events with natural estrogen-based COCs compared to ethinylestradiol-containing pills: A disproportionality analysis of the Eudravigilance database 🌸 Jonathan Douxfils – Effect of E4/DRSP 15/3 mg on Hemostasis Parameters in Post-Menarchal Adolescents: A Phase 3 Multicentre Study 💡 Join us for insightful discussions! We’re particularly eager to connect on the nAPCsr biomarker, a game-changer in assessing thrombotic risk for combined hormonal contraceptive users. Let’s explore how it can help practitioners optimize patient treatment. We’d also love to discuss our ongoing clinical studies and potential collaborations. 📅 Will you be at ESG 2025 next week? Let’s meet! #ESG2025 #Gynecology #Thrombosis #nAPCsr #ClinicalStudies #WomensHealth #Qualiblood

🇮🇹 𝗕𝗶𝗼-𝗘𝘂𝗿𝗼𝗽𝗲 𝗦𝗽𝗿𝗶𝗻𝗴 𝗶𝘀 𝗮𝗿𝗼𝘂𝗻𝗱 𝘁𝗵𝗲 𝗰𝗼𝗿𝗻𝗲𝗿! You want to know more about QUALIblood and how our bioanalytical services can leverage your product development 🧪 ? Just take a few minutes to meet our CEO Julie Winand and discuss about your project and needs 🤝 ☕ . Connect with her directly or schedule a meeting via the BIO-Europe partnering platform!

🌍 Today is International Women’s Day 💜 💭 At QUALIblood, we firmly believe that all women deserve access to effective contraception and medication, as well as safety! ➡️ Did you know that over 1 million women in Belgium are currently on hormonal treatments? These treatments are used for contraception, alleviating menopause symptoms, and managing conditions like endometriosis or breast cancer. However, the thrombotic risks associated with these treatments are often underestimated and overlooked. 💡 By testing thrombotic risk before prescribing with the #nAPCsr, every woman can make an informed choice about her health. 🔬 At QUALIblood, we are committed to scientific innovation and clinical research to ensure that every woman receives the care she deserves. 📢 As we launch various clinical studies to evaluate the relevance of nAPCsr, we are seeking partners to join us in this mission. ⚡ Together, let’s act for women’s health: test, protect, advance. ⚡ #WomensRights #WomensHealth #SafeContraception #Pill #nAPCsr #Endometriosis #Thrombosis #InformedChoice #IWD

📅 3-9 March: European Week for Prevention and Information on Endometriosis 🔎 1 in 10 women of reproductive age suffers from endometriosis. 🌸 Yet, it remains an invisible disease, often misunderstood and underdiagnosed. Many women endure years of heavy pain, dismissed as "normal period cramps," while their condition silently progresses. ⏳ The reality? 🩸 7 to 10 years on average to receive a diagnosis 🤕 70% of affected women experience chronic pain that can be disabling 💊 Hormonal treatments are often the first-line therapy but can carry side effects and impact blood clotting 🤰 1 in 3 women with endometriosis needs assisted reproductive technology (ART) to conceive Yet, despite these alarming numbers, research into diagnostic tools and personalized treatments remains insufficient. At QUALIblood, we are committed to bridging this gap. Our research focuses on how endometriosis and the treatments used to manage it, affect blood clotting and whether biomarkers like #nAPCsr could help assess thrombotic risk. 🤔 Why does this matter? Because women deserve treatments that are not just effective but also safe. 💡 Raising awareness is key. Endometriosis is not “just period pain”, it is a real public health issue. By improving diagnosis, treatment, and follow-up, a real difference can be made in the lives of millions of women. 🔬 At QUALIblood, we believe that scientific innovation and clinical research play a fundamental role in ensuring that every woman receives the care she deserves. QUALIblood remains committed to working alongside healthcare professionals to improve outcomes in women’s health. 📢 As we launch different clinical studies to evaluate the relevance of nAPCsr, we are looking for partners to join us in this mission. Let’s work together to advance research and improve care for women with endometriosis! 👉 Contact us at contact@qualiblood.eu #EndometriosisAwareness #WomensHealth #QUALIblood #Thrombosis #nAPCsr

Thank you Gesellschaft für Thrombose- und Hämostaseforschung e.V., GTH for the organisation and the high quality programmation! #TGA #Innovation #hemostasis #thrombosis #nAPCsr

🩸Great opportunity to meet our researchers and discuss important research topics ! Julie Vassart Laure Morimont

QUALIblood will attend the Gesellschaft für Thrombose- und Hämostaseforschung e.V., GTH2025 Conference this week, from February 18th to 21st 📅 👩🔬 Laure Morimont, PhD, will be thrilled to discuss with you about the #nAPCsr, our leading-edge biomarker, and how this innovation can significantly improve women's health 🌸 Join us in exploring groundbreaking research and fostering meaningful discussions to advance healthcare for women worldwide. 🌍💡 #GTH2025 #nAPCsr #WomensHealth #ThrombinGeneration #HealthcareInnovation

🚀 Big News! 🚀 QUALIblood is partnering with Stago to bring the revolutionary #nAPCsr kit to market 🩸 🤝 ! ✨ This game-changing test will transform thrombosis risk assessment, potentially preventing 13,500 thrombosis cases annually in Europe and saving €1.5 billion in healthcare costs 🏨 . 🔬👩🔬 Through this collaboration, both partners will enhance the performance and clinical validations of the nAPCsr kit, ensuring compliance with the In-Vitro Diagnostic Medical Device Regulation (IVDR) and its integration into clinical practice. 🙏 A huge thank you to Noshaq, NAMUR INVEST, our private supporters and SPW Economie Emploi Recherche for their support. This €2 million initiative is set to redefine personalized medicine. 🎉 Congratulation to the dedicated team for their hard work and commitment. Stay tuned for more updates! 🛑 Full pres release on our website 👉 https://lnkd.in/en_KeTzh #Innovation #Thrombosis #Prevention #Healthcare #Teamwork

🔬 Vers une utilisation plus sûre et responsable des contraceptifs oraux à base d’estrogène 🔬 Hier, j’ai eu l’honneur de présenter un cours-conférence à l’Académie royale des Sciences, des Lettres et des Beaux-Arts de Belgique sur un sujet qui nous mobilise depuis plus de 7 ans au sein de QUALIblood et de l’Unité de Recherche en Pharmacologie Clinique et Toxicologie (URPC) - Namur Research Institute for Life Sciences (NARILIS) de l’Université de Namur: L’évaluation du risque thrombotique associé aux contraceptifs oraux combinés et les solutions pour une prescription plus sûre et personnalisée. Nos recherches, menées avec le soutien de la Fédération Wallonie-Bruxelles et du SPW Economie Emploi Recherche, en partenariat avec le CHU de Clermont-Ferrand - Hémostase CHU Clermont-Ferrand, Estetra, Gedeon Richter et Stago, ont permis d’établir un constat clair: aujourd’hui, grâce aux données biologiques, cliniques et épidémiologiques accumulées, nous disposons d’un bon degré de certitude pour suggérer aux autorités et sociétés expertes: - Un screening avec le #nAPCsr avant la prescription d'un COC - Une évolution des pratiques en faveur des estrogènes naturels (#E2 et #E4), qui présentent un profil de risque significativement plus favorable. 📊 Chiffres clés : ✅ En Europe, on estime à 22 000 le nombre annuel de cas de thrombose liés aux COC. ✅ Le coût sociétal européen de ces événements thromboemboliques dépasse 2 milliards d’euros par an. ✅ La mise en place d’un dépistage ciblé des facteurs de risque et le passage aux estrogènes naturels pourraient permettre d’éviter jusqu’à 17 500 cas de thrombose par an en Europe, réduisant ainsi le fardeau médical et économique de manière significative. 💡 Un changement de paradigme est nécessaire. Les preuves scientifiques sont aujourd’hui solides et plaident en faveur d’une réévaluation des recommandations en matière de contraception hormonale. Il est essentiel que les prescripteurs disposent de toutes les données nécessaires pour garantir aux femmes un accès à une contraception à la fois efficace et sécurisée. Un immense merci à tous mes collaborateurs et collaboratrices d'avoir cru et de croire en ce projet depuis des années: jean-michel Dogné, Jean-Michel Foidart, Mitchell Creinin, Ulysse Gaspard, Bernard Chatelain, Laure Morimont, Julie Winand, Marie Didembourg, Nathalie Donis, Clara DAVID, Clotilde Brisbois, Lucie Raskin, Sébastien Massaux, Charlotte Beaudart, Médéa LOCQUET, Hélène Haguet, Céline Bouvy, Maud Jost, Mélanie Taziaux, Guillaume Chatel, Nina C. Flerin, PhD, Ingrid Rézette, Yvonne Oligschläger, PhD, Merel van Rooijen, Aurélien Lebreton, Wulf Utian, Rogerio Lobo, Kristina Gemzell Danielsson, Arjen PP van Willigenburg, Jean-Francois ARNAL, Nathalie Chabbert-Buffet et tant d'autres centres et chercheurs avec qui nous travaillons chaque jour pour améliorer l'accessibilité à une prescription plus sûres des COC! #Contraception #SantéFéminine #Thrombose #Recherche #Innovation #EBM #Pharmacologie

🌟 Celebrating the International Day of Women and Girls in Science! 🌟 At QUALIblood, we honor the incredible contributions of women in science. Today, we recognize the talented women in our team whose professionalism, passion and dedication drive us every day. Thank you for leading with excellence and shaping the future of science. 🔬✨ Together, these women enhance the research and development of next-generation biomarkers and optimize clinical study outcomes by meticulously handling each patient sample from collection and analysis to data reporting. Join us in celebrating the brilliant minds driving innovation and discovery! 🌍✨ Want to know more about the team ➡️ https://lnkd.in/eSc3Acqx #WomenInScience #GirlsInScience #InternationalDayOfWomenAndGirlsInScience #QUALIblood #STEM #Inspiration #Innovation